Skip to main navigation Skip to search Skip to main content

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19

  • Florence Ader*
  • , Nathan Peiffer-Smadja
  • , Julien Poissy
  • , Maude Bouscambert-Duchamp
  • , Drifa Belhadi
  • , Alpha Diallo
  • , Christelle Delmas
  • , Juliette Saillard
  • , Aline Dechanet
  • , Noémie Mercier
  • , Axelle Dupont
  • , Toni Alfaiate
  • , François Xavier Lescure
  • , François Raffi
  • , François Goehringer
  • , Antoine Kimmoun
  • , Stéphane Jaureguiberry
  • , Jean Reignier
  • , Saad Nseir
  • , François Danion
    • Raphael Clere-Jehl, Kévin Bouiller, Jean Christophe Navellou, Violaine Tolsma, André Cabié, Clément Dubost, Johan Courjon, Sylvie Leroy, Joy Mootien, Rostane Gaci, Bruno Mourvillier, Emmanuel Faure, Valérie Pourcher, Sébastien Gallien, Odile Launay, Karine Lacombe, Jean Philippe Lanoix, Alain Makinson, Guillaume Martin-Blondel, Lila Bouadma, Elisabeth Botelho-Nevers, Amandine Gagneux-Brunon, Olivier Epaulard, Lionel Piroth, Florent Wallet, Jean Christophe Richard, Jean Reuter, Thérèse Staub, Bruno Lina, Marion Noret, DisCoVeRy study group, Myriam Alexandre
*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

90 Citations (Scopus)

Fingerprint

Dive into the research topics of 'An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases